Literature DB >> 12531179

Fitness of drug resistant HIV-1: methodology and clinical implications.

Miguel E Quiñones-Mateu1, Eric J Arts.   

Abstract

Recent studies of human immunodeficiency virus type 1 (HIV-1) fitness have examined the potential relationship with plasma viral load, drug resistance, and disease progression. For example, treatment of HIV-1 infected individuals with antiretroviral drugs may result in the selection and emergence of inhibitor-resistant variants with reduced replicative capacity. However, it is still unclear whether in vitro HIV-1 fitness has any direct relationship to in vivo disease progression or treatment success. A related question is which in vitro assay of viral fitness is the most appropriate for comparison with in vivo HIV-1 fitness. Characterization of the relative viral fitness of drug-resistant HIV-1 strains may lead to a better understanding of whether or not less fit viruses pose a clinical benefit to the patient.

Entities:  

Mesh:

Year:  2002        PMID: 12531179     DOI: 10.1016/s1368-7646(02)00123-1

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  36 in total

Review 1.  Antiretroviral therapy in Africa.

Authors:  Warren Stevens; Steve Kaye; Tumani Corrah
Journal:  BMJ       Date:  2004-01-31

2.  Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing.

Authors:  Matthew J Gonzales; Elizabeth Johnson; Kathryn M Dupnik; Tomozumi Imamichi; Robert W Shafer
Journal:  J Acquir Immune Defic Syndr       Date:  2003-12-01       Impact factor: 3.731

3.  Emergence of mammalian cell-adapted vesicular stomatitis virus from persistent infections of insect vector cells.

Authors:  Isabel S Novella; Bonnie E Ebendick-Corpus; Selene Zárate; Eric L Miller
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

4.  Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.

Authors:  Maame Efua S Sampah; Lin Shen; Benjamin L Jilek; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

5.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

6.  Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression.

Authors:  Ryan M Troyer; Kalonji R Collins; Awet Abraha; Erika Fraundorf; Dawn M Moore; Randall W Krizan; Zahra Toossi; Robert L Colebunders; Mark A Jensen; James I Mullins; Guido Vanham; Eric J Arts
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 7.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

8.  Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

Authors:  Jan Weber; Bikram Chakraborty; Jitka Weberova; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  Only slight impact of predicted replicative capacity for therapy response prediction.

Authors:  Hendrik Weisser; André Altmann; Saleta Sierra; Francesca Incardona; Daniel Struck; Anders Sönnerborg; Rolf Kaiser; Maurizio Zazzi; Monika Tschochner; Hauke Walter; Thomas Lengauer
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

10.  The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses.

Authors:  Xiaohong Kong; John T West; Hong Zhang; Danielle M Shea; Tendai J M'soka; Charles Wood
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.